본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

Journal of viral hepatitis v.24 no.3, 2017년, pp.226 - 237   SCI SCIE
본 등재정보는 저널의 등재정보를 참고하여 보여주는 베타서비스로 정확한 논문의 등재여부는 등재기관에 확인하시기 바랍니다.

Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection

Perelló, C. (Hospital Universitario Puerta de Hierro Majadahonda, IDIPHIM, Madrid, Spain ) ; Carrión, J. A. (Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain ) ; Ruiz‐Antorán, B. (Hospital Universitario Puerta de Hierro Majadahonda, IDIPHIM, Madrid, Spain ) ; Crespo, J. (Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain ) ; Turnes, J. (Complejo Hospitalario Universitario de Pontevedra and IISGS, Pontevedra, Spain ) ; Llaneras, J. (Hospital Universitario Vall D′Hebrón, Barcelona, Spain ) ; Lens, S. (CIBERehd, Madrid, Spain ) ; Delgado, M. (Hospital Universitario A Coruña, A Coruña, Spain ) ; García‐Samaniego, J. (CIBERehd, Madrid, Spain ) ; García‐Paredes, F. (Hospital Universitario Río Hortega, Valladolid, Spain ) ; Fernández, I. ; Morillas, R. M. ; Rincón, D. ; Porres, J. C. ; Prieto, M. ; Lázaro Ríos, M. ; Fernández‐Rodríguez, C. ; Hermo, J. A. ; Rodríguez, M. ; Herrero, J. I. ; Ruiz, P. ; Fernández, J. R. ; Macías, M. ; Pascasio, J. M. ; Moreno, J. M. ; Serra, M. Á. ; Arenas, J. ; Real, Y. ; Jorquera, F. ; Calleja, J. L. ; Rayuela, Federico Sáez ; Simón, Miguel Ángel ; González, José ; Manuel ; Muñoz, Eduardo ; González, Marta ; Jiménez, Miguel ; Moran, Senador ; Vergara‐Gómez, Mercè ; Jiménez, Felipe ; García, Rosa ; Albujar, Alicia Hernández ; Navarro, José ; María ; Antón, María Dolor ;
  • 초록  

    Abstract Over the last 5 years, therapies for hepatitis C virus (HCV) infection have improved significantly, achieving sustained virologic response (SVR) rates of up to 100% in clinical trials in patients with HCV genotype 1. We investigated the effectiveness and safety of ombitasvir/paritaprevir/ritonavir±dasabuvir in an early access programme. This was a retrospective, multicentre, national study that included 291 treatment‐naIve and treatment‐experienced patients with genotype 1 or 4 HCV infection. Most patients (65.3%) were male, and the mean age was 57.5 years. The mean baseline viral load was 6.1 log, 69.8% had HCV 1b genotype, 72.9% had cirrhosis and 34.7% were treatment‐naIve. SVR at 12 weeks posttreatment was 96.2%. Four patients had virological failure (1.4%), one leading to discontinuation. There were no statistical differences in virological response according to genotype or liver fibrosis. Thirty patients experienced serious adverse events (SAEs) (10.3%), leading to discontinuation in six cases. Hepatic decompensation was observed in five patients. Four patients died during treatment or follow‐up, three of them directly related to liver failure. Multivariate analyses showed a decreased probability of achieving SVR associated with baseline albumin, bilirubin and Child‐Pugh score B, and a greater probability of developing SAEs related to age and albumin. This combined therapy was highly effective in clinical practice with an acceptable safety profile and low rates of treatment discontinuation.


  • 주제어

    compassionate use .   dasabuvir .   hepatitis C .   ombitasvir .   paritaprevir .   severe fibrosis.  

 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • 원문이 없습니다.
유료다운로드

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기